Pharma News — Industry Headlines for Field Reps
49 articles covering FDA approvals, layoffs, M&A, drug pricing, and pipeline updates.
Latest Articles
- Takeda Cuts 243 Neuro Reps as Trintellix Patent Cliff Looms — FieldPulse Editorial · March 27, 2026
- Enhertu Gets FDA Priority Review for Early Breast Cancer — PDUFA July 7 — FieldPulse Editorial · March 27, 2026
- Otsuka Pays $1.225B for Transcend's MDMA-Analog PTSD Drug — FieldPulse Editorial · March 27, 2026
- Novartis Acquires Excellergy for Up to $2B, Doubles Down on Allergy — FieldPulse Editorial · March 27, 2026
- Karyopharm's Selinexor Hits Spleen Endpoint but Misses on Symptoms in Myelofibrosis — FieldPulse Editorial · March 26, 2026
- Kodiak's Zenkuda Crushes Phase 3 in Diabetic Retinopathy, Stock Surges 19% — FieldPulse Editorial · March 26, 2026
- Rocket Pharma's Kresladi Wins First-Ever Gene Therapy Approval for LAD-I — FieldPulse Editorial · March 26, 2026
- Novo Nordisk's Awiqli Makes History as First Once-Weekly Insulin — FieldPulse Editorial · March 26, 2026
- Senate Republicans Open Investigation into Mifepristone Marketing as 340B Scrutiny Deepens — FieldPulse Editorial · March 26, 2026
- Novo Nordisk Cuts Wegovy Price in South Africa Again as GLP-1 Global Pricing War Heats Up — FieldPulse Editorial · March 25, 2026
- Maze's APOL1 Kidney Drug Posts Impressive Data — Then the Stock Dropped 31 Percent — FieldPulse Editorial · March 25, 2026
- Sarepta Posts Striking siRNA Data for FSHD and DM1, Signaling a Pivot After a Brutal 2025 — FieldPulse Editorial · March 25, 2026
- Corcept's Lifyorli Wins FDA Approval for Ovarian Cancer Four Months Early — A Major Comeback — FieldPulse Editorial · March 25, 2026
- FDA Clears Denali's Avlayah as First Drug Engineered to Cross the Blood-Brain Barrier — FieldPulse Editorial · March 25, 2026
- Novo Nordisk's Triple-G Agonist Clears Midphase Diabetes Trial, Keeping Pressure on Lilly — FieldPulse Editorial · March 25, 2026
- Merck Bets $6.7B on CML Drug as Keytruda Clock Ticks Down — FieldPulse Editorial · March 25, 2026
- FDA Releases Landmark Guidance on Alternatives to Animal Testing in Drug Development — FieldPulse Editorial · March 24, 2026
- Pfizer's Lyme Disease Vaccine Misses Phase 3 Endpoint Despite Showing 73%+ Efficacy — FieldPulse Editorial · March 24, 2026
- FDA Warns ImmunityBio Over 'False and Misleading' Anktiva Ads Featuring CEO Patrick Soon-Shiong — FieldPulse Editorial · March 24, 2026
- UCB Announces $2B U.S. Biologics Plant in Georgia — Domestic Manufacturing Bet Pays Political Dividends — FieldPulse Editorial · March 24, 2026
- Gilead Moves Beyond HIV with $2.1B Bet on Autoimmune T Cell Engager — FieldPulse Editorial · March 24, 2026
- FTC Moves to Settle with CVS Caremark Over Insulin Pricing — $7B in Savings on the Table — FieldPulse Editorial · March 24, 2026
- Pfizer-Valneva Lyme Vaccine Misses Phase 3 Threshold — But Both Companies Are Pressing Forward — FieldPulse Staff · March 23, 2026
- MFN Drug Pricing vs. Congress: The Policy Fight That Could Rewrite Every Rep's Formulary Position — FieldPulse Staff · March 22, 2026
- Novartis Pays Up to $3B for Synnovation's PI3Kα Inhibitor — A Bet on Its Own Breast Cancer Franchise — FieldPulse Staff · March 22, 2026
Talk · Companies